Inhibikase Therapeutics, Inc.IKTEarnings & Financial Report
Nasdaq
NextApr 25, 2026
IKT Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-12.8M
Net Profit
$-11.9M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.13
Inhibikase Therapeutics, Inc. Q3 2025 Financial Summary
Inhibikase Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-11.9M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-11.9M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Inhibikase Therapeutics, Inc. Annual Revenue by Year
Inhibikase Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2024 | $0 |
| 2023 | $260.5K |
| 2022 | $123.4K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | -100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $14.5M | $11.1M | $8.8M | $4.4M | $98.6M | $94.3M | $88.9M | $79.6M |
| Liabilities | $3.5M | $4.3M | $3.7M | $4.9M | $3.7M | $8.6M | $8.8M | $6.7M |
| Equity | $11.0M | $6.8M | $5.1M | $-530591 | $94.9M | $85.7M | $80.1M | $72.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.4M | $-3.9M | $-5.1M | $-4.9M | $-5.3M | $-4.1M | $-5.6M | $-10.6M |